Amylyx Pharmaceuticals, Inc.

NASDAQ:AMLX

Biotechnology

Healthcare
$26.20 +0.93%

+$0.14 today

Market cap
$3.37B
Beta
-0.16
P/E (TTM)
-11.3
EPS (TTM)
-$1.36
52W Low $4.80High $18.61

Volume 1.76M

Average 1.21M

Returns on capital

Amylyx Pharmaceuticals, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-47.4%

avg -13.9%

ROIC

-49.3%

avg 11.2%

ROA

-43.5%

avg -154.8%

Analysis

ROA is currently the strongest return metric at -43.5% versus its period average of -154.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Justin Klee

Co-CEO & DirectorUSD 1.25M35——

Joshua Cohen

Co-Founder, Co-CEO & DirectorUSD 1.25M34——

Camille L. Bedrosian

Chief Medical OfficerUSD 1.01M73278.06K0.33%

James Frates

Chief Financial OfficerUSD 817.18K59——

Gina Mazzariello

Chief Legal Officer & General CounselUSD 715.49K54190.84K0.23%

Machelle Manuel

Vice President & Head of Global Medical Affairs————

Tom Holmes

Chief Technical Operations Officer————

Linda A. Arsenault

Chief Human Resources Officer————

Lindsey Allen

Head of Investor Relations & Communications————

Tammy Sarnelli

Global Head of Regulatory Affairs————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Sep 10, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

2

$152,183.00

Sells

39

$17.31M

Net Transaction Value

−$17.16M

Net selling

Most Active

FRATES JAMES M

9 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Nov 10, 26

FRATES JAMES M

Direct

Sell$388.1K
Nov 10, 26

FRATES JAMES M

Direct

Sell$223K
Nov 9, 26

Klee Justin B.

Direct

Sell$1.9M
Nov 9, 26

Cohen Joshua B

Direct

Sell$1.1M
Nov 9, 26

Cohen Joshua B

Direct

Sell$1.9M
Nov 9, 26

Klee Justin B.

Direct

Sell$1.1M
Nov 9, 26

FRATES JAMES M

Direct

Sell$226.3K
Nov 9, 26

FRATES JAMES M

Direct

Sell$370.4K
Oct 5, 26

MILNE GEORGE M JR

Direct

Sell$830.9K
Sep 10, 26

Klee Justin B.

Direct

Sell$47.7K

1–10 of 41

Summary

Insiders reported 2 buys worth $152,183.00 and 39 sells worth $17.31M over the last 12 months. That adds up to net selling of $17.16M. FRATES JAMES M was the most active insider with 9 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A2 analysts
RevenueN/AN/AN/A
N/A5 analysts
Net IncomeN/AN/AN/A
N/A5 analysts
EBITN/AN/AN/A
N/A5 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does Amylyx Pharmaceuticals, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about AMLX's management, answered from reported figures.

Who manages AMLX?

Amylyx Pharmaceuticals, Inc. (AMLX) lists 10 active executives. The top listed executive is Justin Klee, Co-CEO & Director.

Are AMLX insiders buying or selling?

Recent insider activity shows net buying of $16.00M.